Journal Watch · Frontiers in Immunology · 2026

Anti-amphiphysin antibody positive autoimmune syndrome: case series and literature review.

Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.

Wang L, Chen J, Tang X et al.Frontiers in Immunology3 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1782004PMID: 41993178Study type: cohort / observational clinical study

TL;DR

Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.

Key findings

  • While strongly associated with malignancies such as breast and small cell lung cancer (SCLC), combined immunotherapy and oncologic therapy can stabilize or improve neurological function in subsets of patients.
  • Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.

What they did

Clinical presentation included conus medullaris-cauda equina syndrome (1/4), myelitis (2/4) and stiff-person syndrome (SPS) (1/4). The coexisting cancer was involved of lung cancer (1/4).<h4>Conclusion</h4>Anti-amphiphysin-IgG-positive autoimmune syndrome demonstrate heterogeneous clinical presentations, including myelitis, SPS, and rare variants like conus medullaris-cauda equina syndrome. Coexistence with other neural antibodies (e.g., AQP4-IgG or NMDAR-IgG) may elevate tumor risk.

Full abstract (original)

Background: <h4>Background and purpose</h4>Paraneoplastic neurological syndromes (PNS) is an uncommon disorder affecting the central nervous system (CNS), peripheral nervous system, or autonomic nervous system. The aim of this study was to analyze the clinical characteristics of anti-amphiphysin-IgG-positive autoimmune syndrome and to assess its association with a spectrum of​ anti-amphiphysin-IgG-associated autoimmune syndromes and tumors.<h4>Methods</h4>We reported clinical data of four patients with anti-amphiphysin-IgG-positive autoimmune syndrome, and conducted a literature review.<h4>Result</h4>Four amphiphysin-IgG-positive cases were identified. Within our cohort, antibodies feature was comprised of isolated amphiphysin-IgG (2/4), coexisting aquaporin-4-immunoglobulin G (AQP4-IgG) (1/4), coexisting N-methyl- D -aspartate receptor immunoglobulin G (NMDAR-IgG) (1/4).

What they did: Clinical presentation included conus medullaris-cauda equina syndrome (1/4), myelitis (2/4) and stiff-person syndrome (SPS) (1/4). The coexisting cancer was involved of lung cancer (1/4).<h4>Conclusion</h4>Anti-amphiphysin-IgG-positive autoimmune syndrome demonstrate heterogeneous clinical presentations, including myelitis, SPS, and rare variants like conus medullaris-cauda equina syndrome. Coexistence with other neural antibodies (e.g., AQP4-IgG or NMDAR-IgG) may elevate tumor risk.

Results & conclusions: While strongly associated with malignancies such as breast and small cell lung cancer (SCLC), combined immunotherapy and oncologic therapy can stabilize or improve neurological function in subsets of patients. Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1782004 · PubMed 41993178.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Clinical presentation included conus medullaris-cauda equina syndrome (1/4), myelitis (2/4) and stiff-person syndrome (SPS) (1/4).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1782004. PubMed ID: 41993178. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wang L, Chen J, Tang X et al.. Anti-amphiphysin antibody positive autoimmune syndrome: case series and literature review.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1782004.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/anti-amphiphysin-antibody-positive-autoimmune-syndrome-case-series-and-l-782004/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides